ClinicalTrials.gg
CompletedNCT00498797Updated Oct 7, 2016Results posted

E3-Hormone Refractory Prostrate Cancer Taxotere Combination

A Phase 2 interventional study of Zactima (vandetanib) and Docetaxel in Prostate Cancer, Metastatic and Hormone Refractory, sponsored by Sanofi. Completed at 11 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-07.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.

Enrollment
50th of 185
86 · median 39
Started
2005
with 20 others
Phase 2
104 of 193
4 open now
Registered
91st of 193
by date
Lead sponsor
11 of 193
Sanofi

Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 50th largest by enrollment of the 185 interventional ones that give a count, is one of 21 that started in 2005, is one of 104 in phase 2, and was the 91st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies testing docetaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether treatment with Zactima (vandetanib) in combination with Docetaxel and Prednisolone is more effective than the standard Docetaxel and Prednisolone alone for prostate cancer, in patients with Hormone refractory prostate cancer who have not previously received chemotherapy.

03

Conditions studied

  • Prostate Cancer
  • Metastatic
  • Hormone Refractory

Keywords

  • prostate cancer
  • zactima
  • vandetanib
  • metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • hormone prostate cancer defined as those patients with evidence of progression of disease in spite of castrate levels of testosterone indicated by rising levels of PSA
  • No previous chemotherapy although those patients that have received estramustine can enter the study provided the estramustine was stopped 3 weeks before dosing of study drug
  • screening PSA values >20ng/ml. this must be confirmed by two separate measurements at least 2 weeks apart

Exclusion criteria

Exclusion Criteria:

  • Treatment within 4 weeks before randomization and/or whilst on study, treatment with the following: 1)non-approved or experimental drug, 2)treatment with a drug with similar mechanism of action to ZD6474
  • concurrent treatment with other anticancer agents, othr than docetaxel and prednisolone as defined in the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
86 participants (actual)
06

What researchers measure

Primary outcomes

  1. Prostate Specific Antigen (PSA) Response

    Prostate Specific Antigen (PSA) response was defined as a reduction of at least 50% from baseline at any assessment, confirmed by a second assessment 2-4 weeks after the initial response

    Time frame: PSA measurements were to be performed at screening, at baseline (>2 weeks after screening) and every 3 weeks during the study. Any response was to be confirmed 2-4 weeks after the initial assessment of a 50% fall in PSA from baseline

Secondary outcomes

  1. Number of Patients With an Objective Disease Progression Event

    Number of patients with objective disease progression or death (by any cause in the absence of objective progression)

    Time frame: RECIST tumour assessments carried out at screening and then as per site clinical practice until objective progression. The only additional mandatory tumour assessment visit is at the point of data cut-off (21 July 2007 or up to 7 days in advance of DCO)

07

Results

Posted May 24, 2011

Participant flow

First patient randomised 24 January 2006, last patient randomised 24 Nov 2006, data cut off data 21 July 2007

Participant flow — Overall Study
MilestoneVandetanibPlacebo
Started4343
Completed514
Not completed3829
Withdrew: Withdrawal by subject42
Withdrew: Adverse event125
Withdrew: Condition under investigation worsened1921
Withdrew: Other31

Outcome measures

PrimaryProstate Specific Antigen (PSA) Response

Prostate Specific Antigen (PSA) response was defined as a reduction of at least 50% from baseline at any assessment, confirmed by a second assessment 2-4 weeks after the initial response

Time frame:
PSA measurements were to be performed at screening, at baseline (>2 weeks after screening) and every 3 weeks during the study. Any response was to be confirmed 2-4 weeks after the initial assessment of a 50% fall in PSA from baseline
Reported as:
Number · Participants
Prostate Specific Antigen (PSA) Response
ParticipantsVandetanibPlacebo
Prostate Specific Antigen (PSA) Response1729
SecondaryNumber of Patients With an Objective Disease Progression Event

Number of patients with objective disease progression or death (by any cause in the absence of objective progression)

Time frame:
RECIST tumour assessments carried out at screening and then as per site clinical practice until objective progression. The only additional mandatory tumour assessment visit is at the point of data cut-off (21 July 2007 or up to 7 days in advance of DCO)
Reported as:
Number · Participants
Number of Patients With an Objective Disease Progression Event
ParticipantsVandetanibPlacebo
Number of Patients With an Objective Disease Progression Event2826

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vandetanib—23/43 (53.5%)38/43 (88.4%)
Placebo—15/43 (34.9%)39/43 (90.7%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventVandetanibPlacebo
PNEUMONIAInfections and infestations3/431/43
FEBRILE NEUTROPENIABlood and lymphatic system disorders2/431/43
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders2/431/43
ANAEMIABlood and lymphatic system disorders0/431/43
NEUTROPENIABlood and lymphatic system disorders1/430/43
ATRIAL FIBRILLATIONCardiac disorders1/431/43
BLINDNESSEye disorders1/430/43
CONSTIPATIONGastrointestinal disorders0/431/43
DIARRHOEAGastrointestinal disorders0/431/43
DUODENAL ULCER HAEMORRHAGEGastrointestinal disorders0/431/43
Most frequent other events
Showing 10 of 48
Most frequent other events
EventVandetanibPlacebo
ALOPECIASkin and subcutaneous tissue disorders16/4319/43
NAUSEAGastrointestinal disorders7/4316/43
FATIGUEGeneral disorders16/4314/43
DIARRHOEAGastrointestinal disorders10/4313/43
CONSTIPATIONGastrointestinal disorders4/4310/43
DYSGEUSIANervous system disorders8/435/43
INSOMNIAPsychiatric disorders8/437/43
LACRIMATION INCREASEDEye disorders4/437/43
VOMITINGGastrointestinal disorders1/437/43
ASTHENIAGeneral disorders5/437/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)VandetanibPlaceboTotal
Mean67 (47 to 81)67 (43 to 79)67 (43 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)VandetanibPlaceboTotal
Female000
Male434386
08

Study locations

11 sites
  • Research site
    Rio de Janeiro, Brazil
  • Research Site
    Sao Paulo, Brazil
  • Research Site
    Hamburg, Germany
  • Research Site
    Hannover, Germany
  • Research Site
    Kassel, Germany
  • Research Site
    Tubingen, Germany
  • Research Site
    Budapest, Hungary
  • Research Site
    Bloemfontein, South Africa
  • Research Site
    Cape Town, South Africa
  • Research Site
    Umea, Sweden
  • Research Site
    Uppsala, Sweden
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Jul 2007 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2007
First posted
Jul 10, 2007
Start
Dec 2005
Primary completionActual
Jul 2007
CompletionActual
Sep 2008
Results first posted
May 24, 2011
Last update
Oct 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00498797
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 10, 2007
Start date
Dec 2005
Primary completion
Jul 2007
Completion
Sep 2008
Results posted
May 24, 2011
Last update
Oct 7, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Prednisolone

Start the discussion